Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourBearish
15 minExpanding
5 minExpanding
Daily trend turns up above $39.14
Key levels
Resistance$39.14
Resistance$36.70
Support$32.84
Support$30.17
Latest news & SEC filings
AnalystOppenheimer Keeps Buy Rating and $75 Target on Definium Therapeutics
AnalystRBC Capital keeps Outperform rating on Definium Therapeutics, lifts target to $70
AnalystRBC Hikes Its Definium Therapeutics Target to $70 From $66
All DFTX news →Definium Therapeutics is a clinical-stage biopharmaceutical company developing treatments for brain health disorders. Its lead candidates are DT120, a refined version of lysergide D-tartrate being studied for anxiety and depression, and DT402, an R-enantiomer of MDMA being developed for autism spectrum disorder. The company operates in the United States and Canada, running clinical trials through third-party sites and contract research organizations.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$48.00
SEPT Mid Target
$72.00
SEPT High Target
$90.00
Analyst Consensus
$72.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DFTX.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$59.30
10
Moat Score
NONE
1/9
Piotroski Score
15.5
Altman Z-Score
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Karlin Daniel | director officer | Sale | 10,853 | $397K | Sep 25, 2026 |
| Barrow Robert | director officer | Sale | 31,550 | $1.2M | Sep 25, 2026 |
| Wiley Matthew T. | officer | Sale | 3,097 | $113K | Sep 25, 2026 |
| Sullivan Mark | officer | Sale | 14,051 | $514K | Sep 25, 2026 |
| Roberts Brandi | officer | Sale | 3,377 | $123K | Sep 25, 2026 |
| Vallone Carol A | director | Buy | 1,086 | $39K | Sep 18, 2026 |
| Krebs Andreas | director | Buy | 1,629 | $58K | Sep 18, 2026 |
| Wiley Matthew T. | officer | Buy | 125,000 | - | Sep 14, 2026 |
| Sullivan Mark | officer | Buy | 125,000 | - | Sep 14, 2026 |
| Roberts Brandi | officer | Buy | 125,000 | - | Sep 14, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-33.77%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for DFTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:26:06 | $34.47 | 7,259 | $$250K | BUY |
| 21:00:31 | $34.47 | 6,876 | $$237K | SELL |
| 21:00:31 | $34.47 | 3,909 | $$135K | SELL |
| 20:57:47 | $34.46 | 3,697 | $$127K | BUY |
| 20:57:39 | $34.48 | 2,066 | $$71K | MIDPOINT |
5 dark pool trades shown · $$821K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for DFTX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $45 | Jan 21 | 436 | $$128.7K | 165 | BLOCK |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for DFTX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $LCLN — Heidloff Theodore J. | Sale $DFTX — Wiley Matthew T. | Sale $DFTX — Sullivan Mark | Sale $DFTX — Roberts Brandi | Sale $PRI — DAY CYNTHIA N | Sale $24K
Smart Money Moves $DFTX — Wiley Matthew T. | Sale $DFTX — Sullivan Mark | Sale $DFTX — Roberts Brandi | Sale $CARE — Midkiff Catharine L. | Sale $31K $OWL — LIPSCHULTZ MARC S | Sale
Smart Money Moves $DJT — Juhan Phillip | Sale $157K $TPL — HORIZON KINETICS ASSET MANAGEMENT LLC | Sale $0K $DFTX — Sullivan Mark | Sale $DFTX — Wiley Matthew T. | Sale $DFTX — Roberts Brandi | Sale
Join 3,500+ traders discussing DFTX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for Definium Therapeutics, Inc. (DFTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Definium Therapeutics, Inc. (DFTX) is at $34.47, down 0.49% (-$0.17) at the Nov 11, 2026 close.
Nov 10, 2026: Definium Therapeutics shares closed at $34.64, up 0.55% on the day, after RBC Capital reiterated its Outperform rating and raised its price target to $70 from $66. The new target implies significant upside from the current price, though the stock traded in a wide range between $33.78 and $35.97 on volume of about 1.27 million shares.
The average analyst price target for DFTX is $72.00, ranging from $48 to $90, based on 13 analysts. Latest: Oppenheimer maintains on Nov 11, 2026.
Analyst ratings for DFTX: 0 Buy, 25 Hold, 0 Sell — consensus Hold.
DFTX last reported on Nov 9, 2026: EPS -$0.46 vs -$0.56 expected — a beat of 18.3%.
DFTX does not currently pay a dividend.
Support: $32.84, $30.17, $26.25. Resistance: $36.70, $39.14, $41.51.
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
Nov 11, 2026: Oppenheimer Keeps Buy Rating and $75 Target on Definium Therapeutics · Nov 10, 2026: RBC Capital keeps Outperform rating on Definium Therapeutics, lifts target to $70 · Nov 10, 2026: RBC Hikes Its Definium Therapeutics Target to $70 From $66